Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to -$6.6 million.

  • Biofrontera's Consolidated Net Income fell 1728.7% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year decrease of 3688.56%. This contributed to the annual value of -$17.8 million for FY2024, which is 1178.28% up from last year.
  • Per Biofrontera's latest filing, its Consolidated Net Income stood at -$6.6 million for Q3 2025, which was down 1728.7% from -$5.3 million recorded in Q2 2025.
  • Biofrontera's 5-year Consolidated Net Income high stood at $5.6 million for Q1 2022, and its period low was -$16.0 million during Q3 2021.
  • Its 5-year average for Consolidated Net Income is -$4.9 million, with a median of -$4.2 million in 2025.
  • In the last 5 years, Biofrontera's Consolidated Net Income skyrocketed by 25735.71% in 2022 and then crashed by 197159.53% in 2025.
  • Biofrontera's Consolidated Net Income (Quarter) stood at -$14.5 million in 2021, then soared by 80.8% to -$2.8 million in 2022, then skyrocketed by 226.61% to $3.5 million in 2023, then plummeted by 139.59% to -$1.4 million in 2024, then plummeted by 376.29% to -$6.6 million in 2025.
  • Its Consolidated Net Income stands at -$6.6 million for Q3 2025, versus -$5.3 million for Q2 2025 and -$4.2 million for Q1 2025.